Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Climb Bio (CLYM) Accumulated Expenses (2020 - 2026)

Climb Bio filings provide 7 years of Accumulated Expenses readings, the most recent being $984000.0 for Q1 2026.

  • Quarterly Accumulated Expenses fell 83.88% to $984000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $984000.0 through Mar 2026, down 83.88% year-over-year, with the annual reading at $1.9 million for FY2025, 53.53% down from the prior year.
  • Accumulated Expenses hit $984000.0 in Q1 2026 for Climb Bio, down from $1.9 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $6.1 million in Q1 2025 and bottomed at $28000.0 in Q4 2023.
  • Average Accumulated Expenses over 5 years is $3.2 million, with a median of $2.9 million recorded in 2024.
  • The largest annual shift saw Accumulated Expenses crashed 98.53% in 2023 before it skyrocketed 14432.14% in 2024.
  • Climb Bio's Accumulated Expenses stood at $1.9 million in 2022, then tumbled by 98.53% to $28000.0 in 2023, then skyrocketed by 14432.14% to $4.1 million in 2024, then crashed by 53.53% to $1.9 million in 2025, then plummeted by 47.96% to $984000.0 in 2026.
  • Per Business Quant, the three most recent readings for CLYM's Accumulated Expenses are $984000.0 (Q1 2026), $1.9 million (Q4 2025), and $1.5 million (Q3 2025).